Egorova, A.; Selutin, A.; Maretina, M.; Selkov, S.; Baranov, V.; Kiselev, A.
Characterization of iRGD-Ligand Modified Arginine-Histidine-Rich Peptides for Nucleic Acid Therapeutics Delivery to αvβ3 Integrin-Expressing Cancer Cells. Pharmaceuticals 2020, 13, 300.
https://doi.org/10.3390/ph13100300
AMA Style
Egorova A, Selutin A, Maretina M, Selkov S, Baranov V, Kiselev A.
Characterization of iRGD-Ligand Modified Arginine-Histidine-Rich Peptides for Nucleic Acid Therapeutics Delivery to αvβ3 Integrin-Expressing Cancer Cells. Pharmaceuticals. 2020; 13(10):300.
https://doi.org/10.3390/ph13100300
Chicago/Turabian Style
Egorova, Anna, Alexander Selutin, Marianna Maretina, Sergei Selkov, Vladislav Baranov, and Anton Kiselev.
2020. "Characterization of iRGD-Ligand Modified Arginine-Histidine-Rich Peptides for Nucleic Acid Therapeutics Delivery to αvβ3 Integrin-Expressing Cancer Cells" Pharmaceuticals 13, no. 10: 300.
https://doi.org/10.3390/ph13100300
APA Style
Egorova, A., Selutin, A., Maretina, M., Selkov, S., Baranov, V., & Kiselev, A.
(2020). Characterization of iRGD-Ligand Modified Arginine-Histidine-Rich Peptides for Nucleic Acid Therapeutics Delivery to αvβ3 Integrin-Expressing Cancer Cells. Pharmaceuticals, 13(10), 300.
https://doi.org/10.3390/ph13100300